CZ283181B6 - Farmaceutická činidla - Google Patents

Farmaceutická činidla Download PDF

Info

Publication number
CZ283181B6
CZ283181B6 CS913756A CS375691A CZ283181B6 CZ 283181 B6 CZ283181 B6 CZ 283181B6 CS 913756 A CS913756 A CS 913756A CS 375691 A CS375691 A CS 375691A CZ 283181 B6 CZ283181 B6 CZ 283181B6
Authority
CZ
Czechia
Prior art keywords
ylmethyl
methoxybenzoyl
methylindol
cyclopentyloxycarbonyl
amino
Prior art date
Application number
CS913756A
Other languages
Czech (cs)
English (en)
Inventor
James Joseph Holohan
Ieuan John Edwards
Robert Joseph Timko
Randy John Bradway
Arlene Clements
Original Assignee
Zeneca Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ283181(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909027014A external-priority patent/GB9027014D0/en
Priority claimed from GB919115107A external-priority patent/GB9115107D0/en
Application filed by Zeneca Limited filed Critical Zeneca Limited
Publication of CS375691A3 publication Critical patent/CS375691A3/cs
Publication of CZ283181B6 publication Critical patent/CZ283181B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CS913756A 1990-12-12 1991-12-11 Farmaceutická činidla CZ283181B6 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909027014A GB9027014D0 (en) 1990-12-12 1990-12-12 Pharmaceutical agents
GB919115107A GB9115107D0 (en) 1991-07-12 1991-07-12 Pharmaceutical agents

Publications (2)

Publication Number Publication Date
CS375691A3 CS375691A3 (en) 1992-06-17
CZ283181B6 true CZ283181B6 (cs) 1998-01-14

Family

ID=26298105

Family Applications (1)

Application Number Title Priority Date Filing Date
CS913756A CZ283181B6 (cs) 1990-12-12 1991-12-11 Farmaceutická činidla

Country Status (30)

Country Link
US (6) US5319097A (fr)
EP (1) EP0490648B1 (fr)
JP (1) JP2585495B2 (fr)
KR (2) KR0183027B1 (fr)
CN (2) CN1043405C (fr)
AP (1) AP285A (fr)
AT (1) ATE131048T1 (fr)
AU (1) AU656157B2 (fr)
BE (1) BE1004229A5 (fr)
CA (2) CA2056066C (fr)
CZ (1) CZ283181B6 (fr)
DE (2) DE4140858A1 (fr)
DK (1) DK0490648T3 (fr)
ES (1) ES2079589T3 (fr)
FI (1) FI101193B (fr)
FR (1) FR2670488B1 (fr)
GB (2) GB2280606B (fr)
GR (1) GR3018318T3 (fr)
HK (2) HK81597A (fr)
HU (2) HU213211B (fr)
IE (1) IE75348B1 (fr)
IL (1) IL100091A (fr)
IT (1) IT1256282B (fr)
MX (1) MX9102473A (fr)
MY (1) MY106315A (fr)
NZ (1) NZ240939A (fr)
PH (1) PH30928A (fr)
RU (1) RU2106140C1 (fr)
SK (2) SK279813B6 (fr)
TW (1) TW276181B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
GB9119001D0 (en) * 1991-09-05 1991-10-23 Ici Plc Pharmaceutical agents
GR1001368B (el) * 1992-10-08 1993-10-29 Ici Plc Φαρμακευτικοί φορείς.
DE4235133A1 (de) * 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
DE9410461U1 (de) * 1994-07-01 1994-09-22 Merck Patent Gmbh, 64293 Darmstadt Mittel für die Röntgenfluoreszenzanalyse
US6279736B1 (en) 1995-04-19 2001-08-28 Capitol Specialty Plastics, Inc. Barrier pack having an absorbing agent applied to the interior of the pack
IN182496B (fr) * 1996-02-20 1999-04-17 Reddy Research Foundation
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
GB9723985D0 (en) * 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6224907B1 (en) * 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
KR100283682B1 (ko) * 1998-07-14 2001-03-02 조정래 열풍건조장치
US6253463B1 (en) 1999-04-26 2001-07-03 Niro A/S Method of spray drying
IN191496B (fr) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
EP1216058A2 (fr) * 1999-09-20 2002-06-26 Alza Corporation Procede destine a reduire la transformation polymorphique d'un medicament
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof
IL140096A0 (en) * 2000-12-05 2002-02-10 Internat Specialty Products Is Process for preparation of zafirlukast
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
TWI337083B (en) * 2001-01-26 2011-02-11 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EP1406880A1 (fr) * 2001-07-10 2004-04-14 PHARMACIA & UPJOHN COMPANY Cristaux a base de thiazine oxazolidinones
EP3168218B1 (fr) * 2001-08-15 2018-11-14 Pharmacia & Upjohn Company LLC Un cristal comprenant un sel d'acide malique de n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide pour utilisation comme un médicament
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ATE345793T1 (de) * 2001-09-21 2006-12-15 Schering Corp Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ATE406364T1 (de) * 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
ES2318274T3 (es) * 2003-03-07 2009-05-01 Schering Corporation Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
EP1855651A4 (fr) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd Compositions nanoparticulaires de derives d'amide heterocyclique
US20070197467A1 (en) * 2006-02-06 2007-08-23 Srinivasulu Rangineni Zafirlukast compositions
US20090012146A1 (en) * 2007-07-02 2009-01-08 Giridhar Reddy Buggana Solubility-enhanced pharmaceutical compositions comprising zafirlukast
CA2695008A1 (fr) * 2007-07-30 2009-02-05 Auspex Pharmaceuticals, Inc. Indoles substitues
US20090149662A1 (en) * 2007-12-05 2009-06-11 Raghupathi Reddy Anumula Processes for preparing zafirlukast
WO2014012954A1 (fr) 2012-07-18 2014-01-23 Takeda Gmbh Traitement de l'asthme sévère partiellement régulé ou non régulé
CA2936332A1 (fr) 2014-01-22 2015-07-30 Takeda Gmbh Traitement de l'asthme grave partiellement controle ou non controle avec un inhibiteur de pde4 (et en combinaison avec un modificateur des leucotrienes)
PT109030B (pt) 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
WO2018140858A1 (fr) 2017-01-30 2018-08-02 Western New England University Inhibiteurs de thiol isomérases et leur utilisation
WO2019130334A1 (fr) 2017-12-28 2019-07-04 Council Of Scientific & Industrial Research Procédé de préparation du zafirlukast et de ses analogues
WO2022243942A1 (fr) 2021-05-19 2022-11-24 Quercis Pharma AG Compositions contenant de la quercétine destinées à être utilisées dans le traitement de la sclérose latérale amyotrophique
WO2023214391A1 (fr) 2022-05-06 2023-11-09 Quercis Pharma AG Méthode de traitement de cancers et de maladies neurologiques à l'aide de compositions contenant de la quercétine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
GB9027018D0 (en) * 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds

Also Published As

Publication number Publication date
FR2670488B1 (fr) 1994-01-28
US6143775A (en) 2000-11-07
CN1043405C (zh) 1999-05-19
DK0490648T3 (da) 1996-05-06
US5482963A (en) 1996-01-09
BE1004229A5 (fr) 1992-10-13
FI101193B1 (fi) 1998-05-15
ITMI913324A0 (it) 1991-12-11
US5504216A (en) 1996-04-02
GB9126354D0 (en) 1992-02-12
FI101193B (fi) 1998-05-15
CA2319308C (fr) 2001-08-21
IL100091A (en) 1998-08-16
KR970005014A (ko) 1997-01-29
GB9418154D0 (en) 1994-10-26
GB2251791B (en) 1995-05-17
US5993859A (en) 1999-11-30
DE69115229D1 (de) 1996-01-18
RU2106140C1 (ru) 1998-03-10
CA2056066C (fr) 2002-04-02
HU213211B (en) 1997-03-28
ATE131048T1 (de) 1995-12-15
TW276181B (fr) 1996-05-21
MX9102473A (es) 1992-06-01
US5319097A (en) 1994-06-07
SK279814B6 (sk) 1999-04-13
AP285A (en) 1993-09-23
SK279813B6 (sk) 1999-04-13
US5612367A (en) 1997-03-18
CA2319308A1 (fr) 1992-06-13
AU656157B2 (en) 1995-01-27
JP2585495B2 (ja) 1997-02-26
KR0183027B1 (ko) 1999-05-01
CA2056066A1 (fr) 1992-06-13
GR3018318T3 (en) 1996-03-31
AP9100340A0 (en) 1992-01-31
CN1243827A (zh) 2000-02-09
CN1062291A (zh) 1992-07-01
HK81397A (en) 1997-06-27
GB2280606A (en) 1995-02-08
HUT61281A (en) 1992-12-28
FI915826A (fi) 1992-03-31
ES2079589T3 (es) 1996-01-16
GB2251791A (en) 1992-07-22
CN1105705C (zh) 2003-04-16
EP0490648B1 (fr) 1995-12-06
KR100207802B1 (ko) 1999-07-15
DE69115229T2 (de) 1996-05-09
FR2670488A1 (fr) 1992-06-19
HU913865D0 (en) 1992-02-28
GB2280606B (en) 1995-05-17
HK81597A (en) 1997-06-27
IE75348B1 (en) 1997-08-27
IE914310A1 (en) 1992-06-17
ITMI913324A1 (it) 1993-06-11
FI915826A0 (fi) 1991-12-11
PH30928A (en) 1997-12-23
EP0490648A1 (fr) 1992-06-17
IL100091A0 (en) 1992-08-18
IT1256282B (it) 1995-11-29
MY106315A (en) 1995-04-29
AU8899491A (en) 1992-06-18
JPH04266824A (ja) 1992-09-22
KR920011493A (ko) 1992-07-24
DE4140858A1 (de) 1992-06-17
NZ240939A (en) 1994-05-26
HU211126A9 (en) 1995-10-30
CS375691A3 (en) 1992-06-17

Similar Documents

Publication Publication Date Title
CZ283181B6 (cs) Farmaceutická činidla
JP5543982B2 (ja) Ｃｏｐｄの処置に有用な５−ピラゾリル−２−ピリドン誘導体のトシル酸塩
CA2056067C (fr) Une forme physique de n-¬4-¬5-(cyclopentyloxcarbony)amino-1-methylindol-3-yl-methyi|-3-methoxybenzoy1|-2-methyibezenesulphonanide, procedes de preparation et les compositions les contenant
KR102572035B1 (ko) 무정형 형태의 빌란테롤 트리페나테이트 및 이의 제조방법
JP2023502011A (ja) レバムロジピンベシル酸塩水和物含有組成物及びその調製方法
JPH10182639A (ja) ドキサゾシン・メシレートの新規な形態ｉ
AU3095600A (en) New pharmaceutical formulation
JPH10182640A (ja) ドキサゾシン・メシレートの新規な形態ｉｉ
FI106021B (fi) Menetelmä N-[4-[5-(syklopentyylioksikarbonyyli)amino-1-metyyli-indol-3-yyli-metyyli]-3-metoksibentsoyyli]-2-metyylibentseenisulfonamidin fysikaalisen muodon valmistamiseksi
PT100508B (pt) Composicoes farmaceuticas e processo para a sua preparacao
HU220769B1 (hu) N-[ 4-(5-/Ciklopentil-oxi-karbonil-amino/-l-metil-indol-3-il-metil)-3-metoxi-benzoil]-2-metil-benzolszulfonamid új fizikai módosulata és eljárás annak előállítására
NO179575B (no) Farmasöytisk preparat inneholdende en fysikalsk form av forbindelsen N-[4-[5-(cyklopentyloksykarbonyl)amino-1-metylindol-3-ylmetyl-3-metoksybenzoylÅ-2-metylbenzensulfonamid

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MK4A Patent expired

Effective date: 20111211